The biotech sector has been weak of late – and as a result now may be the time to get in. Today’s article looks at some of the factors that lie behind the sector’s current performance – including the delay in getting tax reform passed and the “biotech buyout frenzy” that, despite expectations, failed to come to pass this year – and highlights six biotech stocks that may be good candidates for riding a biotech rebound. For more, CLICK HERE.